Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IMUX with free AI briefings, catalyst countdowns, and dilution alerts.

IMUX · IMMUNIC, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$132M Cash on Hand
13.3mo Cash Runway
Follow IMUX by email Get an email when IMUX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IMUX, unsubscribe in one click. Privacy

📣 What IMUX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Vidofludimus Calcium Anhydrous (IMU-838) COVID-19 Phase 2/3 · NCT04379271 Completed
Oseltamivir Covid 19 Phase 2 · NCT04516915 Completed
IMU-935 Metastatic Castration Resistant Prostate Cancer Phase 1 · NCT05124795 Terminated

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IMUX holds $132M in cash and short-term investments (as of Sep 30, 2026) and burns about $29.7M/quarter from operations, an estimated runway of 13.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 33 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IMUX files for a raise →

👥 Who Owns IMUX

Insiders 3% Other 5%+ holders 97% Institutions 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
Vivo Opportunity Fund Holdings, L.P. 5%+ holder (13G) 29,126,906 183.41% 2026-02-17
Avidity Partners Management LP Institution (13G, 5%+) 13,958,410 87.89% 2026-02-17
JANUS HENDERSON GROUP PLC Institution (13G, 5%+) 12,016,444 75.67% 2025-11-28
Deep Track Capital, LP Institution (13G, 5%+) 11,454,000 72.12% 2026-02-17
Trails Edge Capital Partners, LP Institution (13G, 5%+) 11,454,000 72.12% 2026-02-17
Commodore Capital LP Institution (13G, 5%+) 1,511,821 9.52% 2026-06-30
Aberdeen Group plc Institution (13G, 5%+) 1,090,427 6.87% 2026-09-30
Nantahala Capital Management, LLC Institution (13G, 5%+) 1,079,843 6.80% 2026-06-30
Laurion Capital Management LP Institution (13G, 5%+) 839,526 5.29% 2026-06-30
Morgan Stanley Institution (13G, 5%+) 704,244 4.43% 2026-09-30
Daniel Vitt
Director · +2.86M options
Insider 391,877 2.47% 2025-06-04
BVF PARTNERS L P/IL
Director · +25,370 options
Insider 42,762 0.27% 2026-09-16

Share count 15,880,822 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full IMUX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMUX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.